Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma

Our results suggest that trametinib and 4-MU are promising therapeutic agents in MPM and that further study of the combination is warranted.